CRMD — CorMedix Inc. stock price, charts and financials

Latest market price

7.53

+0.09+1.21%

Overview Short InterestFilings

CRMDQT45CorMedix Inc.·NASDAQ

Overview Short InterestFilings

7.53+1.21%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.52%$15.45 MESO+4.64%$16.68 ZBIO-1.48%$31.95 GHRS-2.44%$29.53 TSHA-2.90%$6.37 STOK-1.47%$32.23 ABCL+34.78%$9.34 VRDN-2.25%$23.06

Snapshot

Index	-	P/E	3.13	EPS (ttm)	2.38	Insider Own	12.91%	Shs Outstand	78.45M	Perf Week	-1.20%

Market Cap	583.68M	Forward P/E	84.55	EPS next Y	0.09	Insider Trans	-	Shs Float	66.53M	Perf Month	-14.19%

Enterprise Value	553.01M	PEG	0.00	EPS next Q	-	Inst Own	-	Short Float	23.07%	Perf Quarter	-6.06%

Income	178.61M	P/S	1.46	EPS this Y	-76.11%	Inst Trans	-	Short Ratio	11.76	Perf Half Y	1.22%

Sales	400.07M	P/B	1.35	EPS next Y	-82.54%	ROA	22.19%	Short Interest	15.35M	Perf YTD	-36.03%

Book/sh	-	P/C	2.99	EPS next 5Y	27.69%	ROE	50.38%	52W High	15.14 -50.27%	Perf Year	-37.74%

Cash/sh	-	P/FCF	2.97	EPS past 3/5Y	-	ROIC	27.59%	52W Low	6.20 21.37%	Perf 3Y	79.71%

Dividend Est.	-	EV/EBITDA	2.60	Sales past 3/5Y	-	Gross Margin	85.83%	Volatility	2.53% 4.09%	Perf 5Y	28.06%

Dividend TTM	-	EV/Sales	1.38	EPS Y/Y TTM	803.33%	Oper. Margin	48.41%	ATR (14)	0.31	Perf 10Y	1.92%

Dividend Ex-Date	-	Quick Ratio	2.74	Sales Y/Y TTM	830.23%	Profit Margin	45.25%	RSI (14)	40.47	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	2.98	EPS Q/Q	43.33%	SMA20	-4.70%	Beta	1.47	Target Price	13.50

Payout	0.00%	Debt/Eq	0.34	Sales Q/Q	225.64%	SMA50	-9.41%	Rel Volume	0.58	Prev Close	7.44

Employees	191	LT Debt/Eq	0.37	Earnings	Aug 13	SMA200	-13.08%	Avg Volume	1.28M	Price	7.53

IPO Date	May 13, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.42% 21.38%	Net Debt/EBITDA	-0.14	Volume	740,233	Change	1.21%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Apr-28-26	Reiterated	RBC Capital	Outperform	$13 → $14
Mar-06-26	Reiterated	Leerink Partners		$13
Jan-23-26	Reiterated	HC Wainwright & Co.	Buy	$17 → $13
Jan-21-26	Reiterated	RBC Capital	Outperform	$22 → $13
Jan-08-26	Reiterated	Truist Financial	Buy	$20 → $16
Oct-21-25	Reiterated	RBC Capital	Outperform	$9.00 → $22
Oct-20-25	Upgrade	D. Boral Capital	Hold → Buy
Aug-08-25	Reiterated	HC Wainwright & Co.	Buy	$17
Jun-30-25	Downgrade	D. Boral Capital	Buy → Hold
Mar-13-24	Reiterated	RBC Capital	Outperform	$9.00

Latest News

Aug-07-26

Aug-07-2604:24PM

U.S. District Court Granted Preliminary Approval Of CorMedix Derivative Settlement On July 24; Final Hearing Set For September 23Benzinga

Jul-29-26

Jul-29-2608:30AM

CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026globenewswire.com

Jul-16-26

Jul-16-2608:02AM

Frequency Electronics Posts Weak Q4 Results, Joins AST SpaceMobile And Other Big Stocks Moving Lower In Thursday’s Pre-Market SessionBenzinga

Jul-07-26

Jul-07-2612:11PM

RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13Benzinga

Jul-01-26

Jul-01-2608:02AM

Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market SessionBenzinga

Jun-30-26

Jun-30-2612:10PM

Is CRMD Stock a Buy Now After Strong Growth and New Risks?zacks.com

12:10PM

CRMD's Growth Story Expands Beyond DefenCath Into New Trendszacks.com

12:06PM

CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Pathzacks.com

Company

CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	400	312	43	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	56	36	3	—	—	—	—	—	—
Gross Profit	343	276	40	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	127	30	59	—	—	—	—	—	—
Research and Development	23	19	4	—	—	—	—	—	—
Other Operating Expense	-1	77	0	—	—	—	—	—	—
Operating Income	194	150	-22	—	—	—	—	—	—
Interest Expense	3	3	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-6	3	3	—	—	—	—	—	—
Net Income Before Taxes	185	150	-19	—	—	—	—	—	—
Income Taxes	4	-13	-1	—	—	—	—	—	—
Consolidated Net Income	182	163	-18	—	—	—	—	—	—
Net Income From Continuing Operations	182	163	-18	—	—	—	—	—	—
Net Income	182	163	-18	—	—	—	—	—	—
EPS (Recurring)	2.38	2.25	-0.30	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	2.38	2.25	-0.30	—	—	—	—	—	—
EPS (Diluted)	2.11	2.04	-0.30	—	—	—	—	—	—
EBITDA	213	168	-19	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	3.57	5.70	—	—	—	—	—	—	—
Price To Sales Ratio	1.51	2.68	11.11	—	—	—	—	—	—
Gross Margin	85.75	88.46	93.02	—	—	—	—	—	—
Operating Margin	48.50	48.08	-51.16	—	—	—	—	—	—
Net Margin	45.50	52.24	-41.86	—	—	—	—	—	—
Shares Outstanding	80	72	59	—	—	—	—	—	—
Market Capitalization	602	837	478	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dillione Janet	Director	Jan 21 '26	Sale	6.88	10,000	68,800	38,473	Jan 22
Todisco Joseph	Chief Executive Officer	Jan 16 '26	Option Exercise	3.38	29,585	99,997	521,664	Jan 20
Lefkowitz Steven W	Director	Jan 12 '26	Option Exercise	5.63	15,000	84,450	95,498	Jan 14
DUNTON ALAN W	Director	Dec 30 '25	Option Exercise	4.03	20,000	80,600	60,250	Jan 02
DUNTON ALAN W	Director	Dec 30 '25	Sale	13.00	20,000	260,000	40,250	Jan 02
Todisco Joseph	Chief Executive Officer	Dec 18 '25	Option Exercise	4.43	30,000	132,900	539,496	Dec 19
Todisco Joseph	Chief Executive Officer	Dec 18 '25	Sale	12.00	30,000	360,000	509,496	Dec 19
Dillione Janet	Director	Dec 09 '25	Option Exercise	7.82	34,000	265,900	82,473	Dec 11
Dillione Janet	Director	Dec 09 '25	Sale	12.00	34,000	408,000	48,473	Dec 11
Lefkowitz Steven W	Director	Dec 09 '25	Sale	11.88	40,000	475,200	80,498	Dec 10
Dillione Janet	Director	Dec 02 '25	Option Exercise	3.96	46,657	184,802	95,130	Dec 04
Dillione Janet	Director	Dec 02 '25	Sale	10.00	46,657	466,570	48,473	Dec 04
Dillione Janet	Director	Nov 24 '25	Option Exercise	3.64	26,343	95,948	74,816	Nov 26
Dillione Janet	Director	Nov 24 '25	Sale	9.93	26,343	261,586	48,473	Nov 26
Dillione Janet	Director	Nov 14 '25	Sale	11.42	30,000	342,600	48,473	Nov 18

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.